B Lymphoblastic Leukemia/Lymphoma — Trials

B Lymphoblastic Leukemia/Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

373 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 163
Recruiting: 102
Ph III recruiting: 11
Growth YoY: +17.2%
Industry share: 15%
Top sponsor: National Cancer Institute (NCI)
Termination share: 43.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (49)

clinicaltrialsPublishedShowing 1–50 of 52 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03739814	Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia	recruiting	Phase 2	84	National Cancer Institute (NCI)NIH	2	Sep 29, 2026	clinicaltrials
NCT06124157	A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)	recruiting	Phase 2	222	National Cancer Institute (NCI)